Compare Citius Pharmaceuticals Inc (CTXR) vs Prospect Capital Corporation (PSEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Prospect Capital Corporation — how do they compare? Citius Pharmaceuticals Inc trades at $0.53 (market cap $14.64M), while Prospect Capital Corporation trades at $2.27 (market cap $1.14B). The key difference: Prospect Capital Corporation is far larger — about 77.9× Citius Pharmaceuticals Inc's market cap, and Prospect Capital Corporation pays a 22.03% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | PSEC | |
|---|---|---|
Market Cap | $14.64M | $1.14B |
Sector | Health | Financials |
52-Week High | $1.82 | $3.47 |
52-Week Low | $0.53 | $2.15 |
Enterprise Value | $10.86M | — |
Dividend Yield | — | 22.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
PSEC trades at $2.25, down 0.44% recently, with a bearish technical signal and neutral oscillators. The company shows mixed fundamentals with a low P/B of 0.39 and consistent earnings beats in recent quarters, but negative revenue of -$407M and net income margin of -495.94% for 2025 highlight financial stress. Recent news includes a new investment in ShipOffers and ongoing dividend payments, though sentiment is cautious amid a deep discount to NAV.
The outlook remains challenging due to persistent negative revenue and high yield risks, but the valuation discount and earnings beats offer potential for value investors. Key risks include further NAV erosion and dividend sustainability, while institutional sentiment is divided with 25% buy ratings against 55% hold.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Prospect Capital Corporation
Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests primarily in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.
Read more on PSEC →
